Rosiglitazone accelerates wound healing by improving endothelial precursor cell function and angiogenesis in db/db mice
Background & Aims Endothelial precursor cell (EPC) dysfunction is one of the risk factors for diabetes mellitus (DM) which results in delayed wound healing. Rosiglitazone (RSG) is a frequently prescribed oral glucose-lowering drug. Previous studies have shown the positive effects of RSG on ameli...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2019-10-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/7815.pdf |